4.6 Article

Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uropathology (ENUP)

Journal

HISTOPATHOLOGY
Volume 58, Issue 4, Pages 579-585

Publisher

WILEY-BLACKWELL
DOI: 10.1111/j.1365-2559.2011.03784.x

Keywords

bladder neoplasms; cytokeratin; pathology; reporting; transurethral resection; TURB

Ask authors/readers for more resources

Aims: To collect of information about European practices on handling and reporting of transurethral resection specimens of the bladder. Methods and results: The European Network of Uropathology is a communication network that includes 335 pathology laboratories in 15 western European countries. A web-based questionnaire was answered by 52.2% of members. Some routines were adopted by a majority: formalin fixation (92.5%), separate containers for tumour and resection base (72%) and embedding of the entire specimen (60%). Cancer along/in adipose tissue would be reported as pT3a by 19.5% and non-invasive urothelial carcinoma in prostatic ducts/glands as pT4a by 16.1%. Papillary urothelial neoplasia of low malignant potential is recognized by 72.6% but rarely reported. Immunohistochemistry is rarely or sometimes used for diagnosing bladder cancer by 91.7%, and the most frequently used markers are CK20 (76.9%), CK7 (66.7%) and Ki67 (38.8%). Only 24.8% report prognostic markers, with Ki67 (84.4%) and p53 (64.4%) being most common. Only 50.9% use the International Society of Urological Pathology 1998/World Health Organization (WHO) 2004 grading system, followed by WHO 1973 (43.4%) and WHO 1999 (31.4%). Conclusions: There is still variability in routine practice and a need for standardization of methodologies. These results may be helpful when judging what recommendations are reasonable to issue.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

Using deep learning to detect patients at risk for prostate cancer despite benign biopsies

Bojing Liu, Yinxi Wang, Philippe Weitz, Johan Lindberg, Johan Hartman, Wanzhong Wang, Lars Egevad, Henrik Gronberg, Martin Eklund, Mattias Rantalainen

Summary: This study suggests that deep learning can detect potential prostate cancer in benign prostate biopsies, reducing false negatives and indicating men who could benefit from rebiopsies.

ISCIENCE (2022)

Editorial Material Urology & Nephrology

Low-grade prostate cancer should still be labelled cancer Comment

Kenneth A. Iczkowski, Mariel Molina, Lars Egevad, David G. Bostwick, Geert J. L. H. van Leenders, Francisco G. La Rosa, Theodorus van der Kwast, Daniel M. Berney, Andrew J. Evans, Thomas M. Wheeler, Katia R. M. Leite, Hemamali Samaratunga, John Srigley, Murali Varma, Toyonori Tsuzuki, Marshall Scott Lucia, Elward David Crawford, Richard G. Harris, Philip Stricker, Nathan Lawrentschuk, Henry H. Woo, Neil E. Fleshner, Neal D. Shore, John Yaxley, Ola Bratt, Peter Wiklund, Matthew Roberts, Liang Cheng, Brett Delahunt

BJU INTERNATIONAL (2022)

Article Cell Biology

WHO 2022 classification of penile and scrotal cancers: updates and evolution

S. Menon, H. Moch, D. M. Berney, I. A. Cree, J. R. Srigley, T. Tsuzuki, E. Comperat, A. Hartmann, G. Netto, M. A. Rubin, A. J. Gill, S. Turajlic, P. H. Tan, M. R. Raspollini, S. K. Tickoo, M. B. Amin

Summary: Squamous cell carcinoma (SCC) is the most common malignant tumor of the penis. The 2022 WHO classification reinforces the 2016 classification and subclassifies precursor lesions and tumors into human papillomavirus (HPV)-associated and HPV-independent types. The use of p16 immunohistochemistry is practical for differentiating HPV-associated from HPV-independent penile SCC. The classification and reporting of scrotal tumors is provided for the first time in the fifth edition of the WHO Blue book, following the schema of penile cancer classification.

HISTOPATHOLOGY (2023)

Article Pathology

Use of the ISUP e-learning module improves interrater reliability in prostate cancer grading

Rachel N. Flach, Lars Egevad, Martin Eklund, Theodorus H. van der Kwast, Brett Delahunt, Hemamali Samaratunga, Britt B. M. Suelmann, Peter-Paul M. Willemse, Richard P. Meijer, Paul J. van Diest

Summary: This study investigated the effect of e-learning on the interobserver variability of prostate cancer grading using the ISUP Education web platform. The results showed that e-learning reduced variability in PCa grading, making it a cost-effective method for standardisation of pathology.

JOURNAL OF CLINICAL PATHOLOGY (2022)

Letter Pathology

Late recurrence of renal solitary fibrous tumour in the contralateral kidney

Hemamal Samaratunga, Tony Gianduzzo, Joanna Perry-Keene, Lars Egevad, Brett Delahunt

PATHOLOGY (2023)

Article Cell Biology

Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria

Lars Egevad, Brett Delahunt, Kenneth A. Iczkowski, Theo van der Kwast, Geert J. L. H. van Leenders, Katia R. M. Leite, Chin-Chen Pan, Hemamali Samaratunga, Toyonori Tsuzuki, Nita Mulliqi, Xiaoyi Ji, Henrik Olsson, Masi Valkonen, Pekka Ruusuvuori, Martin Eklund, Kimmo Kartasalo

Summary: There is evidence that cribriform morphology is associated with a worse prognosis for prostatic adenocarcinoma. This study aimed to investigate the reproducibility of cribriform cancer diagnosis in prostate needle biopsies. A panel of nine prostate pathology experts independently reviewed 304 digitised biopsies and achieved a 2/3 consensus diagnosis of cribriform and noncribriform cancer in 90% of the cases. Strict diagnostic criteria were used to identify cribriform patterns and generate a set of consensus cases for standardization.

HISTOPATHOLOGY (2023)

Article Medicine, General & Internal

Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade

M. Alvaro Berbis, David S. McClintock, Andrey Bychkov, Jeroen Van der Laak, Liron Pantanowitz, Jochen K. Lennerz, Jerome Y. Cheng, Brett Delahunt, Lars Egevad, Catarina Eloy, Alton B. Farris III, Filippo Fraggetta, Raimundo Garcia del Moral, Douglas J. Hartman, Markus D. Herrmann, Eva Hollemans, Kenneth A. Iczkowski, Aly Karsan, Mark Kriegsmann, Mohamed E. Salama, John H. Sinard, J. Mark Tuthill, Bethany Williams, Cesar Casado-Sanchez, Victor Sanchez-Turrion, Antonio Luna, Jose Aneiros-Fernandez, Jeanne Shen

Summary: AI is expected to be routinely and impactfully used in pathology practice by 2030, according to experts in the field. This consensus study highlights the anticipated short-to-mid-term impact of AI and raises important practical, ethical, and legal challenges that need to be addressed prior to its clinical implementation.

EBIOMEDICINE (2023)

Article Oncology

Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

Naveen S. Vasudev, Ghislaine Scelo, Kate I. Glennon, Michelle Wilson, Louis Letourneau, Robert Eveleigh, Nazanin Nourbehesht, Madeleine Arseneault, Antoine Paccard, Lars Egevad, Juris Viksna, Edgars Celms, Sharon M. Jackson, Behnoush Abedi-Ardekani, Anne Y. Warren, Peter J. Selby, Sebastian Trainor, Michael Kimuli, Jon Cartledge, Naeem Soomro, Adebanji Adeyoju, Poulam M. Patel, Magdalena B. Wozniak, Ivana Holcatova, Antonin Brisuda, Vladimir Janout, Estelle Chanudet, David Zaridze, Anush Moukeria, Oxana Shangina, Lenka Foretova, Marie Navratilova, Dana Mates, Viorel Jinga, Ljiljana Bogdanovic, Bozidar Kovacevic, Anne Cambon-Thomsen, Guillaume Bourque, Alvis Brazma, Jorg Tost, Paul Brennan, Mark Lathrop, Yasser Riazalhosseini, Rosamonde E. Banks

Summary: Targeted gene sequencing can help in risk prediction and adjuvant treatment decisions for patients with resected localized ccRCC. Mutations in the VHL gene have a significant impact on patient outcomes, independent of other gene mutations. Genomic characterization can personalize treatment discussions and inform future adjuvant trial design.

CLINICAL CANCER RESEARCH (2023)

Article Cell Biology

Measuring cancer burden in prostatic needle core biopsies: simplified assessments outperform complex measurements in assessing outcome: evidence to assist pathologist efficiency and minimize datasets

Daniel M. Berney, Kier Finnegan, Kim Chu, Samson W. Fine, Murali Varma, Jack Cuzick, Luis Beltran

Summary: This study aimed to determine the optimal method of measuring cancer extent in prostate cancer biopsies. The results showed that only the percentage of positive cores (%+cores) was a significant predictor of patient outcome in multivariate models. Thus, we propose using %+cores as a simple method of assessment, which is preferred over more complicated methods.

HISTOPATHOLOGY (2023)

Editorial Material Pathology

Tumour grading: communication is the key

Murali Varma, Brett Delahunt, Liang Cheng, Runjan Chetty, Eva Comperat, Vikram Deshpande, Lars Egevad, Theodorus H. van der Kwast, Antonio Lopez-Beltran, W. Glenn McCluggage

JOURNAL OF CLINICAL PATHOLOGY (2023)

Letter Pathology

Not all tumour necrosis is granular necrosis

Hemamali Samaratunga, Lars Egevad, Brett Delahunt

PATHOLOGY (2023)

Review Pathology

Macroscopic examination of pathology specimens: a critical reappraisal

Murali Varma, Laura C. Collins, Runjan Chetty, Dipti M. Karamchandani, Karen Talia, John Dormer, Monika Vyas, Brendan Conn, Yaileen D. Guzman-Arocho, Adam Jones, Miranda Pring, W. Glenn Mccluggage

Summary: This paper highlights the importance of macroscopic examination and tissue sampling in histopathology reporting and discusses potential solutions and challenges. It emphasizes the need for adequate guidance and supervision in macroscopic examination and highlights the importance of clinical context, specimen fixation, macroscopic descriptions, and tissue sampling.

JOURNAL OF CLINICAL PATHOLOGY (2023)

Article Urology & Nephrology

Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening

Joel Andersson, Thorgerdur Palsdottir, Anna Lantz, Markus Aly, Henrik Gronberg, Lars Egevad, Martin Eklund, Tobias Nordstrom

Summary: The study found that for men with PSA >= 3 ng/ml, a suspicious DRE indicates a more than threefold higher risk of significant prostate cancer. DRE as a variable adds significant precision to the Stockholm3 prediction model.

EUROPEAN UROLOGY OPEN SCIENCE (2022)

Letter Pathology

In Reply: Intraductal Carcinoma of the Prostate and Nuclear Size

Hemamali Samaratunga, Brett Delahunt, John W. Yaxley, Shulammite Johannsen, Lars Egevad

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2022)

No Data Available